Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01373242 · ClinicalTrials.gov registry record · Phase 1
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01373242 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 54 participants.
The verdict
NCT01373242, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The goal of this study will be to increase the reaction threshold (desensitization) of peanut allergic children using peanut sublingual immunotherapy and to determine if the nonreactive state of the immune system persists after treatment has been discontinued (tolerance).
Interventions
- DRUG Liquid peanut extract (Peanut SLIT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01373242
The ClinicalTrials.gov registry entry for NCT01373242 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liquid peanut extract (Peanut SLIT) is the first listed.
NCT01373242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01373242 about?
NCT01373242 is a clinical study titled "Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance". The goal of this study will be to increase the reaction threshold (desensitization) of peanut allergic children using peanut sublingual immunotherapy and to determine if the nonreactive state of the immune system persists after treatment has been discontinued (tolerance).
What is the current status of trial NCT01373242?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2011-06. Estimated completion is 2018-04-16.
What interventions are being tested in trial NCT01373242?
The interventions under investigation include: Liquid peanut extract (Peanut SLIT) (DRUG).
Who is sponsoring clinical trial NCT01373242?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.